A composition that is a human growth hormone receptor antagonist comprising human growth hormone receptor antagonist G120K, wherein at least one amino acid of human growth hormone receptor antagonist G120K has been mutated to cysteine； and a polytethylene glycol molecule (PEG) conjugated to each cysteine residue in the human growth hormone receptor antagonist G120K mutant.
